1-bromo-3-(tert-pentyl)benzene | 865374-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-3-(tert-pentyl)benzene
• 英文别名: bromo-3-tert-pentylbenzene；1-bromo-3-(2-methylbutan-2-yl)benzene
• CAS: 865374-17-0
• 化学式: C₁₁H₁₅Br
• 分子量: 227.144
• InChiKey: BGBRUWVXNLSXGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-bromo-3-(tert-pentyl)benzene 、 4-((1,2,3,4,4a,5-hexahydro-6H-pyrazino[1,2-a]quinoxalin-6-yl)sulfonyl)-N,N-dimethylbenzenesulfonamide 在 RuPhos Pd G₃ 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 以51 %的产率得到N,N-dimethyl-4-((3-(3-(tert-pentyl)phenyl)-1,2,3,4,4a,5-hexahydro-6H-pyrazino[1,2-a]quinoxalin-6-yl)sulfonyl)benzenesulfonamide
  参考文献：
  名称：

  TRPML1/2调节剂化合物、药物组合物及其制备方法和应用

  摘要：

  本发明提供了一种式(I)所示的化合物，可用于治疗或预防与TRPML1/2有关的病症和疾病，以及制备用于此类病症和疾病的药物。#imgabs0#

  公开号：

  CN117659017A
• 作为产物：
  描述：

  2-(3-bromophenyl)butan-2-ol 在 盐酸 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-bromo-3-(tert-pentyl)benzene
  参考文献：
  名称：

  Access to “Friedel–Crafts-Restricted” tert-Alkyl Aromatics by Activation/Methylation of Tertiary Benzylic Alcohols

  摘要：

  Herein we describe a two-step protocol to prepare m-tert-alkylbenzenes. The appropriate tertiary benzylic alcohols are activated with SOCl2 or concentrated HCl and then treated with trimethylaluminum, affording the desired products in 68-97% yields (22 examples). This reaction sequence is successful in the presence of a variety of functional groups, including acid-sensitive and Lewis-basic groups. In addition to t-Bu groups, 1,1-dimethylpropyl and 1-ethyl-1-methylpropyl groups can also be installed using this method.

  DOI：

  10.1021/jo202371c

文献信息

• [EN] [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA<br/>[FR] DÉRIVÉS DE [1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL]-PHÉNYLE OU -PYRIDIN-2-YLE EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE C-THÊTA
  申请人：VERTEX PHARMA

  公开号：WO2009073300A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.

  本发明涉及式(I)和(IA)的化合物，可用作蛋白激酶(1a)的抑制剂。该发明还提供包括所述化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供制备本发明化合物的方法。(a)：特别是蛋白激酶Cθ，其中A和A'独立地为-N-或-C(R+) -。环B是五元或六元饱和碳环或杂环，R1、R2、R3、R4、R5、R6、R7、x和y如本文所述。
• [EN] SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS<br/>[FR] UREE ET CARBAMATE SUBSTITUES, PHENACYL-2-HYDROXY-3-DIAMINOALCANE, ET BENZAMIDE-2-HYDROXY-3-DIAMINOALCANE INHIBITEURS D'ASPARTYL-PROTEASE
  申请人：ELAN PHARM INC

  公开号：WO2005087215A1

  公开（公告）日：2005-09-22

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的至少一种疾病、紊乱和病况。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和病况。
• Substituted Ureas and Carbamates
  申请人：Pulley Shon R.

  公开号：US20080306136A1

  公开（公告）日：2008-12-11

  The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

  本发明提供了式I的化合物：用于治疗阿尔茨海默病和其他类似疾病。这些化合物包括β-分泌酶酶的抑制剂，对于治疗阿尔茨海默病和其他以A beta肽在哺乳动物中沉积为特征的疾病非常有用。本发明的化合物在制药组合物和治疗方法中用于减少A beta肽的形成。
• Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
  申请人：John Varghese

  公开号：US20050261273A1

  公开（公告）日：2005-11-24

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

  本发明涉及乙酰基 2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗至少一种与淀粉样变性相关的疾病、失调和病症。淀粉样变性是指与A-β蛋白异常沉积有关的一系列疾病、失调和状况。
• SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：EP1734942A1

  公开（公告）日：2006-12-27